SelectQuote, Inc. Reports Fourth Quarter of Fiscal Year 2024 Results
SelectQuote (NYSE: SLQT) reported Q4 FY2024 results with revenue of $307.2 million, up from $221.8 million in Q4 FY2023. The company posted a net loss of $31.0 million, improved from a $47.8 million loss last year. Adjusted EBITDA was $14.4 million, compared to -$5.8 million in Q4 FY2023.
For full FY2024, revenue reached $1.3 billion, up from $1.0 billion in FY2023. Net loss narrowed to $34.1 million from $58.5 million. Adjusted EBITDA grew to $117.0 million from $74.3 million.
The company provided FY2025 guidance, projecting revenue of $1.4-$1.5 billion, net loss of $42-$6 million, and Adjusted EBITDA of $90-$120 million. SelectQuote also announced plans for a $100 million commissions receivable securitization to optimize its balance sheet.
SelectQuote (NYSE: SLQT) ha riportato i risultati del Q4 FY2024 con un fatturato di 307,2 milioni di dollari, in aumento rispetto ai 221,8 milioni di dollari del Q4 FY2023. L'azienda ha registrato una perdita netta di 31,0 milioni di dollari, migliorando rispetto alla perdita di 47,8 milioni di dollari dell'anno scorso. L'EBITDA rettificato è stato di 14,4 milioni di dollari, rispetto a -5,8 milioni di dollari nel Q4 FY2023.
Per l'intero FY2024, il fatturato ha raggiunto 1,3 miliardi di dollari, in aumento rispetto a 1,0 miliardi di dollari del FY2023. La perdita netta si è ristretta a 34,1 milioni di dollari rispetto ai 58,5 milioni di dollari. L'EBITDA rettificato è cresciuto a 117,0 milioni di dollari rispetto ai 74,3 milioni di dollari.
L'azienda ha fornito le previsioni per FY2025, prevedendo un fatturato di 1,4-1,5 miliardi di dollari, una perdita netta di 42-6 milioni di dollari e un EBITDA rettificato di 90-120 milioni di dollari. SelectQuote ha anche annunciato piani per una cartolarizzazione di crediti da commissioni di 100 milioni di dollari per ottimizzare il proprio bilancio.
SelectQuote (NYSE: SLQT) reportó los resultados del Q4 FY2024 con ingresos de 307,2 millones de dólares, frente a 221,8 millones de dólares en el Q4 FY2023. La compañía reportó una pérdida neta de 31,0 millones de dólares, mejorando desde una pérdida de 47,8 millones de dólares del año anterior. El EBITDA ajustado fue de 14,4 millones de dólares, en comparación con -5,8 millones de dólares en el Q4 FY2023.
Para el FY2024 completo, los ingresos alcanzaron 1,3 mil millones de dólares, un aumento desde 1,0 mil millones de dólares en el FY2023. La pérdida neta se redujo a 34,1 millones de dólares desde 58,5 millones de dólares. El EBITDA ajustado creció a 117,0 millones de dólares desde 74,3 millones de dólares.
La compañía proporcionó una guía para el FY2025, proyectando ingresos de 1,4-1,5 mil millones de dólares, una pérdida neta de 42-6 millones de dólares y un EBITDA ajustado de 90-120 millones de dólares. SelectQuote también anunció planes para una titulización de cuentas por cobrar de comisiones de 100 millones de dólares para optimizar su balance.
SelectQuote (NYSE: SLQT)는 FY2024 4분기 결과를 보고하며 매출 3억 720만 달러를 기록했으며, 이는 FY2023 4분기 2억 2천 180만 달러에서 증가한 수치입니다. 회사는 순손실 3천 100만 달러를 기록했으며, 이는 지난해 4천 780만 달러 손실에서 개선된 것입니다. 조정된 EBITDA는 1천 440만 달러로, FY2023 4분기의 -5천 800만 달러와 비교됩니다.
FY2024 전체 매출은 13억 달러에 달하며, 이는 FY2023의 10억 달러에서 증가한 수치입니다. 순손실은 3천 410만 달러로 줄어들었으며, 이는 5천 850만 달러에서 감소한 것입니다. 조정된 EBITDA는 1억 1천 700만 달러로 증가하였으며, 이는 7천 430만 달러에서 올라간 수치입니다.
회사는 FY2025에 대한 가이던스를 제공하며, 14억-15억 달러의 매출, 4200만-600만 달러의 순손실 및 9천만-1억 2천만 달러의 조정 EBITDA를 예상하고 있습니다. SelectQuote는 또한 자산 부채 최적화를 위한 1억 달러 규모의 커미션 수취권 증권화를 계획하고 있다고 발표했습니다.
SelectQuote (NYSE: SLQT) a publié ses résultats du Q4 FY2024 avec un revenu de 307,2 millions de dollars, en hausse par rapport à 221,8 millions de dollars au Q4 FY2023. L'entreprise a enregistré une perte nette de 31,0 millions de dollars, améliorée par rapport à une perte de 47,8 millions de dollars l'année dernière. L'EBITDA ajusté était de 14,4 millions de dollars, comparé à -5,8 millions de dollars au Q4 FY2023.
Pour l'ensemble de l'année FY2024, le revenu a atteint 1,3 milliard de dollars, en hausse par rapport à 1,0 milliard de dollars en FY2023. La perte nette a été réduite à 34,1 millions de dollars contre 58,5 millions de dollars. L'EBITDA ajusté a augmenté à 117,0 millions de dollars contre 74,3 millions de dollars.
L'entreprise a fourni des prévisions pour FY2025, projetant un revenu de 1,4 à 1,5 milliard de dollars, une perte nette de 42 à 6 millions de dollars et un EBITDA ajusté de 90 à 120 millions de dollars. SelectQuote a également annoncé des plans pour une titrisation de créances de commissions de 100 millions de dollars afin d'optimiser son bilan.
SelectQuote (NYSE: SLQT) hat die Ergebnisse für Q4 FY2024 mit Umsätzen von 307,2 Millionen Dollar veröffentlicht, was einem Anstieg gegenüber 221,8 Millionen Dollar im Q4 FY2023 entspricht. Das Unternehmen verzeichnete einen Nettoverlust von 31,0 Millionen Dollar, verbessert gegenüber einem Verlust von 47,8 Millionen Dollar im Vorjahr. Das bereinigte EBITDA betrug 14,4 Millionen Dollar, im Vergleich zu -5,8 Millionen Dollar im Q4 FY2023.
Für das gesamte FY2024 erreichten die Einnahmen 1,3 Milliarden Dollar, ein Anstieg von 1,0 Milliarden Dollar im FY2023. Der Nettoverlust verringerte sich auf 34,1 Millionen Dollar, gegenüber 58,5 Millionen Dollar. Das bereinigte EBITDA wuchs auf 117,0 Millionen Dollar, von 74,3 Millionen Dollar.
Das Unternehmen gab eine Prognose für FY2025 ab und rechnet mit Einnahmen von 1,4-1,5 Milliarden Dollar, einem Nettoverlust von 42-6 Millionen Dollar und einem bereinigten EBITDA von 90-120 Millionen Dollar. SelectQuote kündigte außerdem Pläne für eine 100 Millionen Dollar schwere Verbriefung von Provisionen an, um die Bilanz zu optimieren.
- Q4 revenue increased 38.5% year-over-year to $307.2 million
- Q4 net loss improved by 35.1% to $31.0 million
- Q4 Adjusted EBITDA turned positive to $14.4 million from -$5.8 million last year
- Full year revenue grew 30% to $1.3 billion
- Full year Adjusted EBITDA increased 57.5% to $117.0 million
- Healthcare Services segment achieved 5th straight quarter of profitability
- SelectRx members grew 68% year-over-year
- Senior segment Adjusted EBITDA margin remained strong at 25%
- Company still reported net losses for both Q4 and full year
- FY2025 guidance projects continued net losses
- Auto & Home segment revenue declined 4% in Q4
Insights
SelectQuote's Q4 FY2024 results show mixed signals. Revenue grew 38.5% year-over-year to
Key positives include:
- Adjusted EBITDA turned positive at
$14.4 million vs.-$5.8 million last year - Healthcare Services achieved profitability for the 5th straight quarter
- SelectRx members grew
68% year-over-year
However, challenges remain:
- Senior segment saw a
3% decline in approved policies - The company still posted a net loss, albeit reduced
- Guidance for FY2025 suggests continued net losses
The planned
SelectQuote's results reflect broader trends in the insurance and healthcare sectors. The
The company's focus on profitability over volume growth is prudent given market saturation in Medicare Advantage. However, the
The Healthcare Services segment's transition to profitability is promising, indicating potential for diversified revenue streams. This could help buffer against fluctuations in the insurance market. However, investors should monitor the segment's thin
The planned securitization of commissions receivables is an innovative move that could provide needed liquidity, but also signals potential cash flow challenges. This financial engineering may become more common in the industry as companies seek to optimize balance sheets in a rising interest rate environment.
Fourth Quarter of Fiscal Year 2024 – Consolidated Earnings Highlights
-
Revenue of
$307.2 million -
Net loss of
$31.0 million -
Adjusted EBITDA* of
$14.4 million
Fiscal Year 2025 Guidance Ranges:
-
Revenue expected in a range of
$1.4 billion $1.5 billion -
Net loss expected in a range of
$42 million $6 million -
Adjusted EBITDA* expected in a range of
$90 million $120 million
Fourth Quarter Fiscal Year 2024 – Segment Highlights
Senior
-
Revenue of
$114.1 million -
Adjusted EBITDA* of
$27.9 million - Approved Medicare Advantage policies of 107,272
Healthcare Services
-
Revenue of
$145.2 million -
Adjusted EBITDA* of
$0.9 million - Approximately 82,000 SelectRx members
Life
-
Revenue of
$42.1 million -
Adjusted EBITDA* of
$7.2 million
Auto & Home
-
Revenue of
$7.6 million -
Adjusted EBITDA* of
$2.5 million
Consolidated revenue for the fiscal year ended June 30, 2024, was
SelectQuote Chief Executive Officer, Tim Danker, commented, “2024 was another successful and strong year for SelectQuote across both Senior Medicare Advantage distribution and our Healthcare Services business, driven by SelectRx. On a consolidated basis our fiscal year revenue and Adjusted EBITDA outperformed the midpoint of our original forecast by
Mr. Danker continued, “SelectQuote’s unique healthcare information platform remains best positioned as a value creation conduit, efficiently connecting a large and growing population of Americans in need of coverage and care with the best providers, based on each of their distinct personal needs.”
Segment Results
We currently report on four segments: 1) Senior, 2) Healthcare Services, 3) Life, and 4) Auto & Home. The performance measures of the segments include total revenue and Adjusted EBITDA*. Costs of commissions and other services revenue, cost of goods sold-pharmacy revenue, marketing and advertising, selling, general, and administrative, and technical development operating expenses that are directly attributable to a segment are reported within the applicable segment. Indirect costs of revenue, marketing and advertising, selling, general, and administrative, and technical development operating expenses are allocated to each segment based on varying metrics such as headcount. Adjusted EBITDA is our segment profit measure to evaluate the operating performance of our business. We define Adjusted EBITDA as net loss plus: (i) interest expense, net; (ii) benefit for income taxes; (iii) depreciation and amortization; (iv) share-based compensation; (v) goodwill, long-lived asset, and intangible assets impairments; (vi) transaction costs; (vii) loss on disposal of property, equipment and software, net; and (viii) other non-recurring expenses and income. Adjusted EBITDA Margin is calculated as Adjusted EBITDA divided by revenue.
Senior
Financial Results
The following table provides the financial results for the Senior segment for the periods presented:
(in thousands) |
4Q 2024 |
|
4Q 2023 |
|
% Change |
|
FY 2024 |
|
FY 2023 |
|
% Change |
||||||||||
Revenue |
$ |
114,143 |
|
|
$ |
103,592 |
|
|
10 |
% |
|
$ |
655,849 |
|
|
$ |
590,131 |
|
|
11 |
% |
Adjusted EBITDA* |
|
27,872 |
|
|
|
16,147 |
|
|
73 |
% |
|
|
166,744 |
|
|
|
155,077 |
|
|
8 |
% |
Adjusted EBITDA Margin* |
|
24 |
% |
|
|
16 |
% |
|
|
|
|
25 |
% |
|
|
26 |
% |
|
|
||
Operating Metrics
Submitted Policies
Submitted policies are counted when an individual completes an application with our licensed agent and provides authorization to the agent to submit the application to the insurance carrier partner. The applicant may have additional actions to take before the application will be reviewed by the insurance carrier.
The following table shows the number of submitted policies for the periods presented:
|
4Q 2024 |
|
4Q 2023 |
|
% Change |
|
FY 2024 |
|
FY 2023 |
|
% Change |
||
Medicare Advantage |
117,091 |
|
114,383 |
|
2 |
% |
|
720,027 |
|
652,630 |
|
10 |
% |
Medicare Supplement |
456 |
|
539 |
|
(15 |
)% |
|
2,790 |
|
3,444 |
|
(19 |
)% |
Dental, Vision and Hearing |
12,821 |
|
14,668 |
|
(13 |
)% |
|
61,713 |
|
74,181 |
|
(17 |
)% |
Prescription Drug Plan |
404 |
|
351 |
|
15 |
% |
|
3,100 |
|
2,433 |
|
27 |
% |
Other |
1,579 |
|
2,099 |
|
(25 |
)% |
|
5,303 |
|
7,501 |
|
(29 |
)% |
Total |
132,351 |
|
132,040 |
|
— |
% |
|
792,933 |
|
740,189 |
|
7 |
% |
*See “Non-GAAP Financial Measures” below. |
Approved Policies
Approved policies represents the number of submitted policies that were approved by our insurance carrier partners for the identified product during the indicated period. Not all approved policies will go in force.
The following table shows the number of approved policies for the periods presented:
|
4Q 2024 |
|
4Q 2023 |
|
% Change |
|
FY 2024 |
|
FY 2023 |
|
% Change |
||
Medicare Advantage |
107,272 |
|
110,027 |
|
(3 |
)% |
|
625,245 |
|
577,567 |
|
8 |
% |
Medicare Supplement |
307 |
|
435 |
|
(29 |
)% |
|
1,885 |
|
2,619 |
|
(28 |
)% |
Dental, Vision and Hearing |
10,995 |
|
12,884 |
|
(15 |
)% |
|
52,469 |
|
60,824 |
|
(14 |
)% |
Prescription Drug Plan |
545 |
|
350 |
|
56 |
% |
|
3,229 |
|
2,144 |
|
51 |
% |
Other |
2,002 |
|
1,356 |
|
48 |
% |
|
4,836 |
|
5,288 |
|
(9 |
)% |
Total |
121,121 |
|
125,052 |
|
(3 |
)% |
|
687,664 |
|
648,442 |
|
6 |
% |
Lifetime Value of Commissions per Approved Policy
Lifetime value of commissions per approved policy represents commissions estimated to be collected over the estimated life of an approved policy based on multiple factors, including but not limited to, contracted commission rates, carrier mix and expected policy persistency with applied constraints. The lifetime value of commissions per approved policy is equal to the sum of the commission revenue due upon the initial sale of a policy, and when applicable, an estimate of future renewal commissions.
The following table shows the lifetime value of commissions per approved policy for the periods presented:
(dollars per policy): |
4Q 2024 |
|
4Q 2023 |
|
% Change |
|
FY 2024 |
|
FY 2023 |
|
% Change |
||||||
Medicare Advantage |
$ |
847 |
|
$ |
830 |
|
2 |
% |
|
$ |
910 |
|
$ |
877 |
|
4 |
% |
Medicare Supplement |
|
245 |
|
|
1,207 |
|
(80 |
)% |
|
|
967 |
|
|
1,030 |
|
(6 |
)% |
Dental, Vision and Hearing |
|
168 |
|
|
121 |
|
39 |
% |
|
|
114 |
|
|
100 |
|
14 |
% |
Prescription Drug Plan |
|
181 |
|
|
185 |
|
(2 |
)% |
|
|
228 |
|
|
207 |
|
10 |
% |
Other |
|
282 |
|
|
105 |
|
169 |
% |
|
|
115 |
|
|
101 |
|
14 |
% |
Healthcare Services
Financial Results
The following table provides the financial results for the Healthcare Services segment for the periods presented:
(in thousands) |
4Q 2024 |
|
4Q 2023 |
|
% Change |
|
FY 2024 |
|
FY 2023 |
|
% Change |
||||||||||
Revenue |
$ |
145,223 |
|
|
$ |
82,803 |
|
|
75 |
% |
|
$ |
478,508 |
|
|
$ |
252,075 |
|
|
90 |
% |
Adjusted EBITDA* |
|
909 |
|
|
|
1,685 |
|
|
(46 |
)% |
|
|
7,821 |
|
|
|
(22,769 |
) |
|
NM |
|
Adjusted EBITDA Margin* |
|
1 |
% |
|
|
2 |
% |
|
|
|
|
2 |
% |
|
|
(9 |
)% |
|
|
||
*See “Non-GAAP Financial Measures” below. |
Operating Metrics
Members
The total number of SelectRx members represents the amount of active customers to which an order has been shipped and the prescriptions per day represents the total average prescriptions shipped per business day. These two metrics are the primary drivers of revenue for Healthcare Services.
The following table shows the total number of SelectRx members as of the periods presented:
|
|
June 30, 2024 |
|
June 30, 2023 |
Total SelectRx Members |
|
82,385 |
|
49,044 |
The total number of SelectRx members increased by
The following table shows the average prescriptions shipped per day for the periods presented:
|
|
FY 2024 |
|
FY 2023 |
Prescriptions Per Day |
|
18,935 |
|
10,657 |
Combined Senior and Healthcare Services - Consumer Per Unit Economics
The opportunity to leverage our existing database and distribution model to improve access to healthcare services for our consumers has created a need for us to review our key metrics related to our per unit economics. As we think about the revenue and expenses for Healthcare Services, we note that they are derived from the marketing acquisition costs associated with the sale of an MA or MS policy, some of which costs are allocated directly to Healthcare Services, and therefore determined that our per unit economics measure should include components from both Senior and Healthcare Services. See details of revenue and expense items included in the calculation below.
Combined Senior and Healthcare Services consumer per unit economics represents total MA and MS commissions; other product commissions; other revenues, including revenues from Healthcare Services; and operating expenses associated with Senior and Healthcare Services, each shown per number of approved MA and MS policies over a given time period. Management assesses the business on a per-unit basis to help ensure that the revenue opportunity associated with a successful policy sale is attractive relative to the marketing acquisition cost. Because not all acquired leads result in a successful policy sale, all per-policy metrics are based on approved policies, which is the measure that triggers revenue recognition.
The MA and MS commission per MA/MS policy represents the LTV for policies sold in the period. Other commission per MA/MS policy represents the LTV for other products sold in the period, including DVH prescription drug plan, and other products, which management views as additional commission revenue on our agents’ core function of MA/MS policy sales. Pharmacy revenue per MA/MS policy represents revenue from SelectRx, and other revenue per MA/MS policy represents revenue from Population Health, production bonuses, marketing development funds, lead generation revenue, and adjustments from the Company’s reassessment of its cohorts’ transaction prices. Total operating expenses per MA/MS policy represents all of the operating expenses within Senior and Healthcare Services. The revenue to customer acquisition cost (“CAC”) multiple represents total revenue as a multiple of total marketing acquisition cost, which represents the direct costs of acquiring leads. These costs are included in marketing and advertising expense within the total operating expenses per MA/MS policy.
The following table shows combined Senior and Healthcare Services consumer per unit economics for the periods presented. Based on the seasonality of Senior and the fluctuations between quarters, we believe that the most relevant view of per unit economics is on a rolling 12-month basis. All per MA/MS policy metrics below are based on the sum of approved MA/MS policies, as both products have similar commission profiles.
|
Twelve Months Ended June 30, |
||||||
(dollars per approved policy): |
2024 |
|
2023 |
||||
MA and MS approved policies |
|
627,130 |
|
|
|
580,186 |
|
MA and MS commission per MA / MS policy |
$ |
910 |
|
|
$ |
877 |
|
Other commission per MA/MS policy |
|
12 |
|
|
|
12 |
|
Pharmacy revenue per MA/MS policy |
|
741 |
|
|
|
412 |
|
Other revenue per MA/MS policy |
|
146 |
|
|
|
150 |
|
Total revenue per MA / MS policy |
|
1,809 |
|
|
|
1,451 |
|
Total operating expenses per MA / MS policy |
|
(1,530 |
) |
|
|
(1,224 |
) |
Adjusted EBITDA per MA/MS policy * |
$ |
279 |
|
|
$ |
227 |
|
Adjusted EBITDA Margin per MA/MS policy * |
|
15 |
% |
|
|
16 |
% |
Revenue / CAC multiple |
4.5X |
|
4.1X |
||||
Total revenue per MA/MS policy increased
Life
Financial Results
The following table provides the financial results for the Life segment for the periods presented:
(in thousands) |
4Q 2024 |
|
4Q 2023 |
|
% Change |
|
FY 2024 |
|
FY 2023 |
|
% Change |
||||||||||
Revenue |
$ |
42,074 |
|
|
$ |
38,052 |
|
|
11 |
% |
|
$ |
157,930 |
|
|
$ |
145,832 |
|
|
8 |
% |
Adjusted EBITDA* |
|
7,217 |
|
|
|
6,702 |
|
|
8 |
% |
|
|
20,164 |
|
|
|
23,073 |
|
|
(13 |
)% |
Adjusted EBITDA Margin* |
|
17 |
% |
|
|
18 |
% |
|
|
|
|
13 |
% |
|
|
16 |
% |
|
|
||
Operating Metrics
Life premium represents the total premium value for all policies that were approved by the relevant insurance carrier partner and for which the policy document was sent to the policyholder and payment information was received by the relevant insurance carrier partner during the indicated period. Because our commissions are earned based on a percentage of total premium, total premium volume for a given period is the key driver of revenue for our Life segment.
The following table shows term and final expense premiums for the periods presented:
(in thousands) |
4Q 2024 |
|
4Q 2023 |
|
% Change |
|
FY 2024 |
|
FY 2023 |
|
% Change |
||||||
Term Premiums |
$ |
18,074 |
|
$ |
20,507 |
|
(12 |
)% |
|
$ |
70,450 |
|
$ |
68,941 |
|
2 |
% |
Final Expense Premiums |
|
23,789 |
|
|
18,960 |
|
25 |
% |
|
|
86,600 |
|
|
77,725 |
|
11 |
% |
Total |
$ |
41,863 |
|
$ |
39,467 |
|
6 |
% |
|
$ |
157,050 |
|
$ |
146,666 |
|
7 |
% |
*See “Non-GAAP Financial Measures” below. |
Auto & Home
Financial Results
The following table provides the financial results for the Auto & Home segment for the periods presented:
(in thousands) |
4Q 2024 |
|
4Q 2023 |
|
% Change |
|
FY 2024 |
|
FY 2023 |
|
% Change |
||||||||||
Revenue |
$ |
7,580 |
|
|
$ |
(1,266 |
) |
(1) |
699 |
% |
|
$ |
36,228 |
|
|
$ |
21,862 |
|
(1) |
66 |
% |
Adjusted EBITDA* |
|
2,474 |
|
|
|
(7,235 |
) |
(1) |
NM |
|
|
14,127 |
|
|
|
81 |
|
(1) |
NM |
||
Adjusted EBITDA Margin* |
|
33 |
% |
|
|
NM |
|
|
|
|
|
39 |
% |
|
|
— |
% |
|
|
||
(1) Decrease is due to the impact of the |
Operating Metrics
Auto & Home premium represents the total premium value of all new policies that were approved by our insurance carrier partners during the indicated period. Because our commissions are earned based on a percentage of total premium, total premium volume for a given period is the key driver of revenue for our Auto & Home segment.
The following table shows premiums for the periods presented:
(in thousands): |
4Q 2024 |
|
4Q 2023 |
|
% Change |
|
FY 2024 |
|
FY 2023 |
|
% Change |
||||||
Premiums |
$ |
13,891 |
|
$ |
14,460 |
|
(4 |
)% |
|
$ |
56,637 |
|
$ |
50,917 |
|
11 |
% |
*See “Non-GAAP Financial Measures” below. |
Earnings Conference Call
SelectQuote, Inc. will host a conference call with the investment community on September 13, 2024, beginning at 8:30 a.m. ET. To register for this conference call, please use this link: https://www.netroadshow.com/events/login?show=7297aa9f&confId=70516. After registering, a confirmation will be sent via email, including dial-in details and unique conference call codes for entry. Registration is open through the live call, but to ensure you are connected for the full call we suggest registering at least 10 minutes before the start of the call. The event will also be webcasted live via our investor relations website https://ir.selectquote.com/investor-home/default.aspx.
Non-GAAP Financial Measures
This release includes certain non-GAAP financial measures intended to supplement, not substitute for, comparable GAAP measures. To supplement our financial statements presented in accordance with GAAP and to provide investors with additional information regarding our GAAP financial results, we have presented in this release Adjusted EBITDA and Adjusted EBITDA Margin, which are non-GAAP financial measures. These non-GAAP financial measures are not based on any standardized methodology prescribed by GAAP and are not necessarily comparable to similarly titled measures presented by other companies. We define Adjusted EBITDA as net income (loss) before interest expense, income tax expense (benefit), depreciation and amortization, and certain add-backs for non-cash or non-recurring expenses, including restructuring and share-based compensation expenses. The most directly comparable GAAP measure is net income (loss). We define Adjusted EBITDA Margin as Adjusted EBITDA divided by revenue. The most directly comparable GAAP measure is net income margin. We monitor and have presented in this release Adjusted EBITDA and Adjusted EBITDA Margin because they are key measures used by our management and Board of Directors to understand and evaluate our operating performance, to establish budgets, and to develop operational goals for managing our business. In particular, we believe that excluding the impact of these expenses in calculating Adjusted EBITDA can provide a useful measure for period-to-period comparisons of our core operating performance. We believe that these non-GAAP financial measures help identify underlying trends in our business that could otherwise be masked by the effect of the expenses that we exclude in the calculations of these non-GAAP financial measures. Accordingly, we believe that these financial measures provide useful information to investors and others in understanding and evaluating our operating results, enhancing the overall understanding of our past performance and future prospects. Reconciliations of net income (loss) to Adjusted EBITDA are presented below beginning on page 13.
Forward Looking Statements
This release contains forward-looking statements. These forward-looking statements reflect our current views with respect to, among other things, future events and our financial performance. These statements are often, but not always, made through the use of words or phrases such as “may,” “should,” “could,” “predict,” “potential,” “believe,” “will likely result,” “expect,” “continue,” “will,” “anticipate,” “seek,” “estimate,” “intend,” “plan,” “projection,” “would” and “outlook,” or the negative version of those words or other comparable words or phrases of a future or forward-looking nature. These forward-looking statements are not historical facts, and are based on current expectations, estimates and projections about our industry, management’s beliefs and certain assumptions made by management, many of which, by their nature, are inherently uncertain and beyond our control. Accordingly, we caution you that any such forward-looking statements are not guarantees of future performance and are subject to risks, assumptions and uncertainties that are difficult to predict. Although we believe that the expectations reflected in these forward-looking statements are reasonable as of the date made, actual results may prove to be materially different from the results expressed or implied by the forward-looking statements.
There are or will be important factors that could cause our actual results to differ materially from those indicated in these forward-looking statements, including, but not limited to, the following: impacts of the COVID-19 pandemic and any other significant public health events; our reliance on a limited number of insurance carrier partners and any potential termination of those relationships or failure to develop new relationships; existing and future laws and regulations affecting the health insurance market; changes in health insurance products offered by our insurance carrier partners and the health insurance market generally; insurance carriers offering products and services directly to consumers; changes to commissions paid by insurance carriers and underwriting practices; competition with brokers, exclusively online brokers and carriers who opt to sell policies directly to consumers; competition from government-run health insurance exchanges; developments in the
About SelectQuote:
Founded in 1985, SelectQuote (NYSE: SLQT) provides solutions that help consumers protect their most valuable assets: their families, health, and property. The company pioneered the model of providing unbiased comparisons from multiple, highly-rated insurance companies allowing consumers to choose the policy and terms that best meet their unique needs. Two foundational pillars underpin SelectQuote’s success: a strong force of highly-trained and skilled agents who provide a consultative needs analysis for every consumer, and proprietary technology that sources and routes high-quality leads.
With an ecosystem offering high touchpoints for consumers across Insurance, Medicare, Pharmacy, and Value-Based Care, the company now has four core business lines: SelectQuote Senior, SelectQuote Healthcare Services, SelectQuote Life, and SelectQuote Auto and Home. SelectQuote Senior serves the needs of a demographic that sees around 10,000 people turn 65 each day with a range of Medicare Advantage and Medicare Supplement plans. SelectQuote Healthcare Services is comprised of the SelectRx Pharmacy, a specialized medication management pharmacy, and Population Health which proactively connects its members with best-in-class healthcare services that fit each member's unique healthcare needs. The platform improves health outcomes and lowers healthcare costs through proactive engagement and access to high-value healthcare solutions.
SELECTQUOTE, INC. AND SUBSIDIARIES |
|||||||
CONSOLIDATED BALANCE SHEETS |
|||||||
(Unaudited) |
|||||||
(In thousands) |
|||||||
|
June 30, 2024 |
|
June 30, 2023 |
||||
ASSETS |
|
|
|
||||
CURRENT ASSETS: |
|
|
|
||||
Cash and cash equivalents |
$ |
42,690 |
|
|
$ |
83,156 |
|
Accounts receivable, net of allowances of |
|
150,035 |
|
|
|
154,565 |
|
Commissions receivable-current |
|
119,871 |
|
|
|
111,148 |
|
Other current assets |
|
20,327 |
|
|
|
14,355 |
|
Total current assets |
|
332,923 |
|
|
|
363,224 |
|
COMMISSIONS RECEIVABLE—Net |
|
761,446 |
|
|
|
729,350 |
|
PROPERTY AND EQUIPMENT—Net |
|
18,973 |
|
|
|
27,452 |
|
SOFTWARE—Net |
|
13,978 |
|
|
|
14,740 |
|
OPERATING LEASE RIGHT-OF-USE ASSETS |
|
23,437 |
|
|
|
23,563 |
|
INTANGIBLE ASSETS—Net |
|
10,194 |
|
|
|
10,200 |
|
GOODWILL |
|
29,438 |
|
|
|
29,136 |
|
OTHER ASSETS |
|
3,519 |
|
|
|
21,586 |
|
TOTAL ASSETS |
$ |
1,193,908 |
|
|
$ |
1,219,251 |
|
|
|
|
|
||||
LIABILITIES AND SHAREHOLDERS’ EQUITY |
|
|
|
||||
CURRENT LIABILITIES: |
|
|
|
||||
Accounts payable |
$ |
36,587 |
|
|
$ |
27,577 |
|
Accrued expenses |
|
16,904 |
|
|
|
16,993 |
|
Accrued compensation and benefits |
|
57,594 |
|
|
|
49,966 |
|
Operating lease liabilities—current |
|
4,709 |
|
|
|
5,175 |
|
Current portion of long-term debt |
|
45,854 |
|
|
|
33,883 |
|
Contract liabilities |
|
8,066 |
|
|
|
1,691 |
|
Other current liabilities |
|
4,873 |
|
|
|
1,972 |
|
Total current liabilities |
|
174,587 |
|
|
|
137,257 |
|
LONG-TERM DEBT, NET—less current portion |
|
637,480 |
|
|
|
664,625 |
|
DEFERRED INCOME TAXES |
|
37,478 |
|
|
|
39,581 |
|
OPERATING LEASE LIABILITIES |
|
25,685 |
|
|
|
27,892 |
|
OTHER LIABILITIES |
|
1,877 |
|
|
|
2,926 |
|
Total liabilities |
|
877,107 |
|
|
|
872,281 |
|
|
|
|
|
||||
COMMITMENTS AND CONTINGENCIES |
|
|
|
||||
|
|
|
|
||||
SHAREHOLDERS’ EQUITY: |
|
|
|
||||
Common stock, |
|
1,694 |
|
|
|
1,669 |
|
Additional paid-in capital |
|
580,764 |
|
|
|
567,266 |
|
Accumulated deficit |
|
(269,769 |
) |
|
|
(235,644 |
) |
Accumulated other comprehensive income |
|
4,112 |
|
|
|
13,679 |
|
Total shareholders’ equity |
|
316,801 |
|
|
|
346,970 |
|
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY |
$ |
1,193,908 |
|
|
$ |
1,219,251 |
|
SELECTQUOTE, INC. AND SUBSIDIARIES |
|||||||||||||||
CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS |
|||||||||||||||
(Unaudited) |
|||||||||||||||
(In thousands) |
|||||||||||||||
|
Three Months Ended June 30, |
|
Year Ended June 30, |
||||||||||||
|
2024 |
|
2023 |
|
2024 |
|
2023 |
||||||||
REVENUE: |
|
|
|
|
|
|
|
||||||||
Commissions and other services |
$ |
165,656 |
|
|
$ |
141,873 |
|
|
$ |
856,923 |
|
|
$ |
763,301 |
|
Pharmacy |
|
141,552 |
|
|
|
79,905 |
|
|
|
464,853 |
|
|
|
239,547 |
|
Total revenue |
|
307,208 |
|
|
|
221,778 |
|
|
|
1,321,776 |
|
|
|
1,002,848 |
|
|
|
|
|
|
|
|
|
||||||||
OPERATING COSTS AND EXPENSES: |
|
|
|
|
|
|
|
||||||||
Cost of commissions and other services revenue |
|
64,548 |
|
|
|
65,697 |
|
|
|
318,798 |
|
|
|
301,524 |
|
Cost of goods sold—pharmacy revenue |
|
120,644 |
|
|
|
71,211 |
|
|
|
405,004 |
|
|
|
225,963 |
|
Marketing and advertising |
|
70,181 |
|
|
|
63,521 |
|
|
|
358,858 |
|
|
|
301,245 |
|
Selling, general, and administrative |
|
43,993 |
|
|
|
49,856 |
|
|
|
141,042 |
|
|
|
136,518 |
|
Technical development |
|
9,233 |
|
|
|
7,154 |
|
|
|
33,524 |
|
|
|
26,015 |
|
Total operating costs and expenses |
|
308,599 |
|
|
|
257,439 |
|
|
|
1,257,226 |
|
|
|
991,265 |
|
|
|
|
|
|
|
|
|
||||||||
INCOME (LOSS) FROM OPERATIONS |
|
(1,391 |
) |
|
|
(35,661 |
) |
|
|
64,550 |
|
|
|
11,583 |
|
|
|
|
|
|
|
|
|
||||||||
INTEREST EXPENSE, NET |
|
(23,409 |
) |
|
|
(21,721 |
) |
|
|
(93,551 |
) |
|
|
(80,606 |
) |
OTHER EXPENSE, NET |
|
(15 |
) |
|
|
(3 |
) |
|
|
(65 |
) |
|
|
(121 |
) |
LOSS BEFORE INCOME TAX EXPENSE (BENEFIT) |
|
(24,815 |
) |
|
|
(57,385 |
) |
|
|
(29,066 |
) |
|
|
(69,144 |
) |
INCOME TAX EXPENSE (BENEFIT) |
|
6,202 |
|
|
|
(9,547 |
) |
|
|
5,059 |
|
|
|
(10,600 |
) |
|
|
|
|
|
|
|
|
||||||||
NET LOSS |
$ |
(31,017 |
) |
|
$ |
(47,838 |
) |
|
$ |
(34,125 |
) |
|
$ |
(58,544 |
) |
|
|
|
|
|
|
|
|
||||||||
NET LOSS PER SHARE: |
|
|
|
|
|
|
|
||||||||
Basic |
$ |
(0.18 |
) |
|
$ |
(0.29 |
) |
|
$ |
(0.20 |
) |
|
$ |
(0.35 |
) |
Diluted |
$ |
(0.18 |
) |
|
$ |
(0.29 |
) |
|
$ |
(0.20 |
) |
|
$ |
(0.35 |
) |
|
|
|
|
|
|
|
|
||||||||
WEIGHTED-AVERAGE COMMON STOCK OUTSTANDING USED IN PER SHARE AMOUNTS: |
|
|
|
|
|
|
|
||||||||
Basic |
|
169,204 |
|
|
|
166,709 |
|
|
|
168,519 |
|
|
|
166,140 |
|
Diluted |
|
169,204 |
|
|
|
166,709 |
|
|
|
168,519 |
|
|
|
166,140 |
|
|
|
|
|
|
|
|
|
||||||||
OTHER COMPREHENSIVE INCOME (LOSS) NET OF TAX: |
|
|
|
|
|
|
|
||||||||
Change in cash flow hedge |
|
(2,364 |
) |
|
|
605 |
|
|
|
(9,567 |
) |
|
|
1,963 |
|
OTHER COMPREHENSIVE INCOME (LOSS) |
|
(2,364 |
) |
|
|
605 |
|
|
|
(9,567 |
) |
|
|
1,963 |
|
COMPREHENSIVE LOSS |
$ |
(33,381 |
) |
|
$ |
(47,233 |
) |
|
$ |
(43,692 |
) |
|
$ |
(56,581 |
) |
SELECTQUOTE, INC. AND SUBSIDIARIES |
||||||||||||||||
CONSOLIDATED STATEMENTS OF CASH FLOWS |
||||||||||||||||
(Unaudited) |
||||||||||||||||
(In thousands) |
||||||||||||||||
|
|
Three Months Ended June 30, |
|
Year Ended June 30, |
||||||||||||
|
|
2024 |
|
2023 |
|
2024 |
|
2023 |
||||||||
CASH FLOWS FROM OPERATING ACTIVITIES: |
|
|
|
|
|
|
|
|
||||||||
Net loss |
|
$ |
(31,017 |
) |
|
$ |
(47,838 |
) |
|
$ |
(34,125 |
) |
|
$ |
(58,544 |
) |
Adjustments to reconcile net loss to net cash and cash equivalents used in operating activities: |
|
|
|
|
|
|
|
|
||||||||
Depreciation and amortization |
|
|
6,407 |
|
|
|
6,794 |
|
|
|
24,998 |
|
|
|
27,881 |
|
Loss on disposal of property, equipment, and software |
|
|
523 |
|
|
|
364 |
|
|
|
536 |
|
|
|
754 |
|
Impairment of long-lived assets |
|
|
— |
|
|
|
17,332 |
|
|
|
— |
|
|
|
17,332 |
|
Share-based compensation expense |
|
|
3,304 |
|
|
|
2,785 |
|
|
|
13,816 |
|
|
|
11,310 |
|
Deferred income taxes |
|
|
3,314 |
|
|
|
(9,760 |
) |
|
|
1,163 |
|
|
|
(11,176 |
) |
Amortization of debt issuance costs and debt discount |
|
|
1,279 |
|
|
|
2,426 |
|
|
|
6,142 |
|
|
|
8,676 |
|
Write-off of debt issuance costs |
|
|
— |
|
|
|
— |
|
|
|
293 |
|
|
|
710 |
|
Accrued interest payable in kind |
|
|
5,254 |
|
|
|
3,565 |
|
|
|
19,577 |
|
|
|
12,015 |
|
Non-cash lease expense |
|
|
404 |
|
|
|
1,070 |
|
|
|
2,349 |
|
|
|
4,185 |
|
Changes in operating assets and liabilities: |
|
|
|
|
|
|
|
|
||||||||
Accounts receivable, net |
|
|
103,722 |
|
|
|
37,921 |
|
|
|
5,203 |
|
|
|
(24,817 |
) |
Commissions receivable |
|
|
(48,194 |
) |
|
|
(18,964 |
) |
|
|
(40,819 |
) |
|
|
(1,872 |
) |
Other assets |
|
|
653 |
|
|
|
(2,997 |
) |
|
|
(1,967 |
) |
|
|
169 |
|
Accounts payable and accrued expenses |
|
|
(28,726 |
) |
|
|
(10,089 |
) |
|
|
7,347 |
|
|
|
(3,649 |
) |
Operating lease liabilities |
|
|
(1,095 |
) |
|
|
(1,312 |
) |
|
|
(4,897 |
) |
|
|
(5,643 |
) |
Other liabilities |
|
|
4,167 |
|
|
|
12,161 |
|
|
|
15,620 |
|
|
|
3,292 |
|
Net cash provided by (used in) operating activities |
|
|
19,995 |
|
|
|
(6,542 |
) |
|
|
15,236 |
|
|
|
(19,377 |
) |
CASH FLOWS FROM INVESTING ACTIVITIES: |
|
|
|
|
|
|
|
|
||||||||
Purchases of property and equipment |
|
|
(268 |
) |
|
|
(391 |
) |
|
|
(3,382 |
) |
|
|
(1,447 |
) |
Proceeds from sales of property and equipment |
|
|
— |
|
|
|
— |
|
|
|
253 |
|
|
|
— |
|
Purchases of software and capitalized software development costs |
|
|
(2,219 |
) |
|
|
(1,874 |
) |
|
|
(8,284 |
) |
|
|
(7,678 |
) |
Acquisition of business |
|
|
(3,433 |
) |
|
|
— |
|
|
|
(3,433 |
) |
|
|
— |
|
Net cash used in investing activities |
|
|
(5,920 |
) |
|
|
(2,265 |
) |
|
|
(14,846 |
) |
|
|
(9,125 |
) |
CASH FLOWS FROM FINANCING ACTIVITIES: |
|
|
|
|
|
|
|
|
||||||||
Payments on Term Loans |
|
|
(8,471 |
) |
|
|
— |
|
|
|
(38,883 |
) |
|
|
(17,833 |
) |
Payments on other debt |
|
|
(37 |
) |
|
|
(35 |
) |
|
|
(149 |
) |
|
|
(158 |
) |
Proceeds from common stock options exercised and employee stock purchase plan |
|
|
74 |
|
|
|
— |
|
|
|
81 |
|
|
|
1,187 |
|
Payments of tax withholdings related to net share settlement of equity awards |
|
|
(1 |
) |
|
|
— |
|
|
|
(374 |
) |
|
|
(40 |
) |
Payments of debt issuance costs |
|
|
(758 |
) |
|
|
— |
|
|
|
(1,531 |
) |
|
|
(10,110 |
) |
Payment of acquisition holdback |
|
|
— |
|
|
|
(50 |
) |
|
|
— |
|
|
|
(2,385 |
) |
Net cash used in financing activities |
|
|
(9,193 |
) |
|
|
(85 |
) |
|
|
(40,856 |
) |
|
|
(29,339 |
) |
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS |
|
|
4,882 |
|
|
|
(8,892 |
) |
|
|
(40,466 |
) |
|
|
(57,841 |
) |
CASH AND CASH EQUIVALENTS—Beginning of period |
|
|
37,808 |
|
|
|
92,048 |
|
|
|
83,156 |
|
|
|
140,997 |
|
CASH AND CASH EQUIVALENTS—End of period |
|
$ |
42,690 |
|
|
$ |
83,156 |
|
|
$ |
42,690 |
|
|
$ |
83,156 |
|
SELECTQUOTE, INC. AND SUBSIDIARIES |
|||||||||||||||
Adjusted EBITDA to Loss before income tax expense (benefit) Reconciliation |
|||||||||||||||
(Unaudited) |
|||||||||||||||
|
Three Months Ended June 30, 2024 |
||||||||||||||
(in thousands) |
Senior |
|
Healthcare
|
|
Life |
|
Auto &
|
|
Total |
||||||
Adjusted Segment EBITDA |
$ |
27,872 |
|
$ |
909 |
|
$ |
7,217 |
|
$ |
2,474 |
|
$ |
38,472 |
|
Corporate & elimination of intersegment profits |
|
|
|
|
|
|
|
|
|
(24,115 |
) |
||||
Adjusted EBITDA |
|
|
|
|
|
|
|
|
|
14,357 |
|
||||
|
|
|
|
|
|
|
|
|
|
||||||
Share-based compensation expense |
|
|
|
|
|
|
|
|
|
(3,304 |
) |
||||
Transaction costs |
|
|
|
|
|
|
|
|
|
(5,529 |
) |
||||
Depreciation and amortization |
|
|
|
|
|
|
|
|
|
(6,407 |
) |
||||
Loss on disposal of property, equipment, and software |
|
|
|
|
|
|
|
|
|
(523 |
) |
||||
Interest expense, net |
|
|
|
|
|
|
|
|
|
(23,409 |
) |
||||
Loss before income tax expense (benefit) |
|
|
|
|
|
|
|
|
$ |
(24,815 |
) |
||||
|
Three Months Ended June 30, 2023 |
|||||||||||||||
(in thousands) |
Senior |
|
Healthcare
|
|
Life |
|
Auto &
|
|
Total |
|||||||
Adjusted Segment EBITDA |
$ |
16,147 |
|
$ |
1,685 |
|
$ |
6,702 |
|
$ |
(7,235 |
) |
|
$ |
17,299 |
|
Corporate & elimination of intersegment profits |
|
|
|
|
|
|
|
|
|
(23,122 |
) |
|||||
Adjusted EBITDA |
|
|
|
|
|
|
|
|
|
(5,823 |
) |
|||||
|
|
|
|
|
|
|
|
|
|
|||||||
Share-based compensation expense |
|
|
|
|
|
|
|
|
|
(2,785 |
) |
|||||
Transaction costs |
|
|
|
|
|
|
|
|
|
(2,568 |
) |
|||||
Depreciation and amortization |
|
|
|
|
|
|
|
|
|
(6,793 |
) |
|||||
Loss on disposal of property, equipment, and software |
|
|
|
|
|
|
|
|
|
(363 |
) |
|||||
Impairment of long-lived assets |
|
|
|
|
|
|
|
|
|
(17,332 |
) |
|||||
Interest expense, net |
|
|
|
|
|
|
|
|
|
(21,721 |
) |
|||||
Loss before income tax expense (benefit) |
|
|
|
|
|
|
|
|
$
|
(57,385
|
)
|
|||||
|
Year Ended June 30, 2024 |
||||||||||||||
(in thousands) |
Senior |
|
Healthcare
|
|
Life |
|
Auto &
|
|
Total |
||||||
Adjusted Segment EBITDA |
$ |
166,744 |
|
$ |
7,821 |
|
$ |
20,164 |
|
$ |
14,127 |
|
$ |
208,856 |
|
Corporate & elimination of intersegment profits |
|
|
|
|
|
|
|
|
|
(91,863 |
) |
||||
Adjusted EBITDA |
|
|
|
|
|
|
|
|
|
116,993 |
|
||||
|
|
|
|
|
|
|
|
|
|
||||||
Share-based compensation expense |
|
|
|
|
|
|
|
|
|
(13,816 |
) |
||||
Transaction costs |
|
|
|
|
|
|
|
|
|
(13,158 |
) |
||||
Depreciation and amortization |
|
|
|
|
|
|
|
|
|
(24,998 |
) |
||||
Loss on disposal of property, equipment, and software |
|
|
|
|
|
|
|
|
|
(536 |
) |
||||
Interest expense, net |
|
|
|
|
|
|
|
|
|
(93,551 |
) |
||||
Loss before income tax expense (benefit) |
|
|
|
|
|
|
|
|
$ |
(29,066 |
) |
||||
|
Year Ended June 30, 2023 |
|||||||||||||||
(in thousands) |
Senior |
|
Healthcare
|
|
Life |
|
Auto &
|
|
Total |
|||||||
Adjusted Segment EBITDA |
$ |
155,077 |
|
$ |
(22,769 |
) |
|
$ |
23,073 |
|
$ |
81 |
|
$ |
155,462 |
|
Corporate & elimination of intersegment profits |
|
|
|
|
|
|
|
|
|
(81,159 |
) |
|||||
Adjusted EBITDA |
|
|
|
|
|
|
|
|
|
74,303 |
|
|||||
|
|
|
|
|
|
|
|
|
|
|||||||
Share-based compensation expense |
|
|
|
|
|
|
|
|
|
(11,310 |
) |
|||||
Transaction costs |
|
|
|
|
|
|
|
|
|
(5,569 |
) |
|||||
Depreciation and amortization |
|
|
|
|
|
|
|
|
|
(27,881 |
) |
|||||
Loss on disposal of property, equipment, and software |
|
|
|
|
|
|
|
|
|
(749 |
) |
|||||
Impairment of long-lived assets |
|
|
|
|
|
|
|
|
|
(17,332 |
) |
|||||
Interest expense, net |
|
|
|
|
|
|
|
|
|
(80,606 |
) |
|||||
Loss before income tax expense (benefit) |
|
|
|
|
|
|
|
|
$ |
(69,144 |
) |
|||||
SELECTQUOTE, INC. AND SUBSIDIARIES |
|||||||
Net Loss to Adjusted EBITDA Reconciliation |
|||||||
(Unaudited) |
|||||||
Guidance net loss to Adjusted EBITDA reconciliation, year ending June 30, 2025: |
|||||||
(in thousands) |
Range |
||||||
Net loss |
$ |
(42,000 |
) |
|
$ |
(6,000 |
) |
Income tax benefit |
|
(16,000 |
) |
|
|
(2,000 |
) |
Interest expense, net |
|
102,000 |
|
|
|
92,000 |
|
Depreciation and amortization |
|
24,000 |
|
|
|
20,000 |
|
Share-based compensation expense |
|
16,000 |
|
|
|
13,000 |
|
Transaction costs |
|
6,000 |
|
|
|
3,000 |
|
Adjusted EBITDA |
$ |
90,000 |
|
|
$ |
120,000 |
|
View source version on businesswire.com: https://www.businesswire.com/news/home/20240913301009/en/
Investor Relations:
Sloan Bohlen
877-678-4083
investorrelations@selectquote.com
Media:
Matt Gunter
913-286-4931
matt.gunter@selectquote.com
Source: SelectQuote, Inc.
FAQ
What were SelectQuote's Q4 2024 financial results?
How did SelectQuote's full year 2024 performance compare to 2023?
What is SelectQuote's revenue guidance for fiscal year 2025?
How much did SelectQuote's SelectRx members grow in fiscal year 2024?
What was the performance of SelectQuote's Senior segment in Q4 2024?
